The firm's Narcan product is more than just a lifesaving treatment for opioid overdose. It's a brilliant, salient campaign, as well.
MM&M hosted an event in Boston devoted to discussing topics and trends for the DTC marketer.
You've seen what the biggies can do. What about the smaller end of the spectrum? MM&M's second buyer's guide to pharma, healthcare, and life sciences consulting services focuses on the dos and don'ts of hiring boutique firms.
Scott Dulitz, SVP, Corporate Strategy, Business Development for TrialCard, outlines how embracing the modern hub allows brands to reach their full potential.
Jim Boushie, director of respiratory marketing at Boehringer Ingelheim (BI) and David Laros, VP of analytics and commercial effectiveness at Aptus Health, came together to lead a joint ePharma session in March titled "Synchronized HCP and consumer campaigns: At the point of care and beyond."
The 2018 MM&M/Publicis Health Diversity Survey is open.
With pharma facing ongoing scrutiny of its pricing practices, medical marketers are increasingly asked to demonstrate the superior value of new therapies. High-profile candidates in immunology, pain management, and melanoma challenge marketers well in advance of launch.
Marketers discuss the biggest catalysts for use of behavioral science techniques in marketing.
Alok Sonig, chief executive officer of developed markets at Dr. Reddy's Laboratories, articulates the benefits of generics.
With healthcare evolving from a fee-for-service system toward one that bases payment on outcomes, marketers must speak to customers in value-oriented messages.
Following massive strikes by Opdivo and Keytruda, will more supersized campaigns follow?
We considered pharma and healthcare ads that, per iSpotTV, started airing no earlier than January 2017.
AI, wearables, and VR still reign supreme in the healthcare realm, and other things you missed
Walmart and Humana have started acquisition talks; Blue Cross and Blue Shield says opioids should not be the first treatment option to manage pain
What happens in the world of Facebook cannot be ignored in pharma marketing. It increasingly lives in a world of data that is highly sensitive and must be managed well.
PhRMA has released a series of new ads that blame high drug prices on cost increases to insurers and PBMs; Veterans Affairs Secretary Dr. David Shulkin has been fired; UK biotech Redx has suspended a Phase I/II trial of its cancer drug
PBMs began by providing a huge service to payers, but in recent years, they've begun to suck revenue from pharma manufacturers. Will they take some heat for high drug prices?
Industry opponents say the end is nigh for pharma's ability to deduct expenses for consumer drug advertising, but those who've found their calling in healthcare comms ought to have something to say about that.
The council, made up of seasoned pharma execs, will function as consultants to rbb's health clients and health team.
Pharma companies are likely to put up aggressive resistance to the measure, introduced earlier this month.
AI's marketing problem: Inflated claims, outsized expectations may actually be slowing AI's move into clinical practiceMarch 21, 2018
The potential is real, but companies and technology gurus often speak of machine learning as a catch-all solution. The hype may be slowing AI's incremental growth in healthcare, experts say.
MM&M has announced its annual showcase of executives, investors, entrepreneurs, designers and thinkers who are ushering the industry into its new technological golden era.
Want to get an ethicist agitated? Mention the integration of voice-activation and other tech into healthcare. Experts say navigating this area is a work in progress.
Recently, Forbes ran an article from Wild Pixel Media founder and CEO Carlos Machicao lamenting the fact that healthcare advertising is boring.
Pharma has backed a number of AR-based games for physician learning and marketing. They're meant to complement live learning, but mobile games may do a better job teaching certain skills.
The pharmaceutical company is undergoing a global restructuring as it relaunches its brand in the U.S. and Canada.
Purdue's decision to pull OxyContin sales reps highlights what has been the biggest part of marketing budgets. Did we just see the tipping point?
The company is also looking to better combine its web and social media presence.
Amazon moves into medical supply market; Big Pharma gets a tax cut; Former Celgene CEO plans Senate run.
There was so much bigger-picture coverage of pharma and healthcare in 2017 - pricing, Affordable Care Act reform and repeal - that it was easy to lose sight of everything else. PwC's Health Research Institute has used its annual look-ahead report to spotlight a handful of undercover trends.